Actively Recruiting
Safety and Tolerability Study of BI 3822971 in Adults With Advanced or Metastatic Solid Cancers
Led by Boehringer Ingelheim · Updated on 2026-10-27
137
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well the medicine BI 3822971 is tolerated in adults with advanced or metastatic solid cancers, including non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, esophageal squamous cell carcinoma, bladder cancer, vulvar cancer, and cervical cancer. The study focuses on adults who have no remaining standard treatment options and have measurable tumors outside the central nervous system. This is a first-in-human, phase I trial aimed at finding a safe and tolerable dose and dosing schedule of BI 3822971, which is being developed to help the immune system fight cancer. All participants receive BI 3822971, with dosing schedules that may change based on data collected during the trial. There is no placebo or randomization in this study. Participants visit the study site regularly and may need to stay overnight for observation on days when the medicine is given. They can remain in the study for up to three years as long as they continue to benefit and tolerate the treatment. Throughout the study, doctors regularly monitor tumor size, general health, and any side effects. Blood samples are also collected to gather information on participant health. The main outcomes measured are treatment-related adverse events and dose-limiting toxicities, with pharmacokinetics also evaluated. Participants receive ongoing health checks and assessments during the study period, which may last up to 36 months.
CONDITIONS
Brief Title
A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Research Team
B
Boehringer Ingelheim
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here